ARTL - Artelo Biosciences - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ARTL is currently covered by 2 analysts with an average price target of $40.36. This is a potential upside of $28.5 (240.3%) from yesterday's end of day stock price of $11.86.

Artelo Biosciences's activity chart (see below) currently has 3 price targets and 22 ratings on display. The stock rating distribution of ARTL is 93.75% BUY and 6.25% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 47.5% with an average time for these price targets to be met of 108.75 days.

Highest price target for ARTL is $20, Lowest price target is $5, average price target is $12.5.

Most recent stock forecast was given by JASON KOLBERT from D. BORAL CAPITAL on 08-Jul-2025. First documented stock forecast 12-Feb-2021.

Best performing analysts who are covering ARTL - Artelo Biosciences:

Jason Kolbert Vernon Bernardino Jason Mccarthy Michael Higgins

Currently out of the existing stock ratings of ARTL, 15 are a BUY (93.75%), 1 are a HOLD (6.25%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$20

$8.14 (68.63%)

26 days ago
(08-Jul-2025)

7/7 (100%)

$4.1 (25.79%)

63

Buy

$5

$-6.86 (-57.84%)

$5

4 months 30 days ago
(04-Mar-2025)

9/10 (90%)

$3.93 (367.29%)

372

Buy

$105

2 years 4 months ago
(03-Apr-2023)

0/1 (0%)

$65.1 (163.16%)

Buy

$75

$71.79 (2236.45%)

$120

4 years 5 months 18 days ago
(17-Feb-2021)

0/2 (0%)

$40.88 (71.42%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ARTL (Artelo Biosciences) average time for price targets to be met?

On average it took 108.75 days on average for the stock forecasts to be realized with a an average price target met ratio 47.5

Which analyst has the current highest performing score on ARTL (Artelo Biosciences) with a proven track record?

JASON KOLBERT

Which analyst has the current lower performing score on ARTL (Artelo Biosciences) with a proven track record?

MICHAEL HIGGINS

Which analyst has the most public recommendations on ARTL (Artelo Biosciences)?

Jason Kolbert has 5 price targets and 5 ratings on ARTL

Which analyst is the currently most bullish on ARTL (Artelo Biosciences)?

Jason Mccarthy with highest potential upside - $71.79

Which analyst is the currently most reserved on ARTL (Artelo Biosciences)?

Vernon Bernardino with lowest potential downside - -$6.86

Artelo Biosciences in the News

Artelo Biosciences stock surges after receiving favorable UK regulatory guidance

Investing.com — Artelo Biosciences (NASDAQ:ARTL) stock surged 18% after the company received favorable guidance from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for a Phase 1 trial of its proprietary CBD:TMP cocrystal being developed for anxiety and depression treatment. The clinical-stage pharmaceutical company announced that the MHRA agreed to a streamlined clinical trial...

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc.(“Artelo” or the “Company”) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that it has received written scientific advice from the UK’s Medicines and Healthcare products Regulatory...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?